Stock·NYSE·Healthcare
Thermo Fisher Scientific Inc. (TMO)
- Market cap
- $253.24B
- P/E
- 36.12
- Dividend yield
- 0.27%
- Street target
- $721.50median of 28 analysts
- 52-week range
- $435.27 $705.79
TMO stock forecast today
Where TMO stands today, and what CleaRank Financial AI makes of it.
TMO at a glance
Thermo Fisher Scientific Inc. (TMO): Buy, 74/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($646.89 and $549.67).
- Earnings TMO beat estimates in 7 of the 7 reports in our data, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $172.4M and made no open-market purchases over the last 18 months.
- Valuation P/E of 36.1 against 31.9 for the Healthcare sector: broadly in line with peers (+13%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Thermo Fisher Scientific Inc. (TMO) a Buy, with a model score of 74/100.
Trend lifts that score the most. The price sits 24.60% above its 200-day average and 5.87% above its 50-day average, and the 50-day average is 17.69% above the 200-day. Valuation is the main drag, with the P/S of 5.35 57.3% above the sector median. The 50-day average is $646.89 and the 200-day is $549.67. The price rose 19.63% over the past year.
Only on CleaRank
Figures we compute ourselves from TMO's own price, earnings and insider-filing history. Tap one to see it in context.
TMO stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $684.89 is 5.9% above the 50-day simple moving average of $646.89.Price above its 200-day average ›
The price is 24.6% above the 200-day simple moving average of $549.67.50-day average above the 200-day ›
The 50-day average ($646.89) is 17.7% above the 200-day average ($549.67), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 92% of its 52-week range, between $435.27 and $705.79.
TMO share price
Pick a period: each tab shows how far TMO has moved over it, to the last close.
Today's trading
Where TMO sits inside today's range and its 52-week range.
TMO fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 36.12 is 13.2% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 5.35 is 57.3% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $7.1B on revenue of $47.4B, a net margin of 14.9%.Beat estimates in most recent reports ›
TMO beat the EPS estimate in 7 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 0.27%, or $1.84 a share a year.
Key statistics
The headline figures for TMO.
As of October 26, 2026, TMO trades at $684.89, with a market value of $253.24B, a P/E ratio of 36.12 and a dividend yield of 0.27%.
What the numbers say
CleaRank Financial AI's reading of TMO's valuation, growth and risks.
Thermo Fisher Scientific Inc. (TMO) trades at 35.54 times trailing earnings, which is 11.4% above the Healthcare median of 31.9. The peer comparison on this page rates that P/E as broadly in line with peers. On sales, the stock is priced at 5.26 times, 54.7% above the sector median of 3.4. TMO has a market capitalisation of $253.2B and trailing earnings of $18.96 per share.
The business earns a net margin of 14.94% and an operating margin of 20.19% and a return on equity of 13.38%, above the sector median of 7.3%. The balance sheet and payout round out the picture, with debt-to-equity of 0.75 and a trailing dividend yield of 0.27% ($1.84 a share a year).
The October 21, 2026 report showed EPS of $6.68, compared with an estimate of $6.40, a beat of 4.38%. Despite the beat, the share price dropped 2.52% in the first session after the report.
Across the 7 reports in our data, TMO beat the estimate every time, though the stock still fell in the first session after 4 of those 7 beats. Looking ahead, analysts expect EPS of $25.26 this fiscal year (growth of 10.5%) and $27.74 the year after (growth of 9.8%).
Over the past 30 days, the standard deviation of TMO's daily returns has been 1.61%. Its beta against the S&P 500 is 0.88.
TMO against the Healthcare sector
How TMO compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (13% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 14, 2025, TMO has gained 68.7% against a gain of 39.2% for XLV.
Performance against XLV
TMO and the Healthcare sector fund over the same days.
Revenue and earnings
How much TMO sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); TMO reported again on October 21, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 3.9% in FY2025 to $44.6B, from $42.9B a year earlier.
Profit margin: The net margin was 15.1% in FY2025, up from 14.8% the year before.
Profitable: TMO earned $6.7B in FY2025.
Earnings reality check
Did TMO beat what analysts expected, and how did the stock react?
Earnings record: TMO beat the analyst estimate in 7 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 4 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 21, 2026after close | $6.40 | $6.68 | +4.38% | -2.52% | - |
| Jul 23, 2026after close | $5.71 | $6.03 | +5.60% | -0.71% | +0.78% |
| Apr 23, 2026after close | $5.24 | $5.44 | +3.82% | +0.64% | +2.63% |
| Oct 22, 2025after close | $5.50 | $5.79 | +5.27% | +0.83% | -1.57% |
| Jul 23, 2025after close | $5.23 | $5.36 | +2.49% | +1.78% | +2.26% |
| Apr 23, 2025after close | $5.10 | $5.15 | +0.98% | -1.15% | -0.61% |
| Jan 30, 2025after close | $5.94 | $6.10 | +2.69% | -1.48% | -5.61% |
As of October 26, 2026, TMO has beaten the analyst EPS estimate in 7 of the 7 reports in our data and fell in the first trading session after 4 of those beats; its latest report, on October 21, 2026, came in 4.38% above the estimate and the stock moved -2.52% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
TMO AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 57.8, in neutral territory.RSI above 50 ›
An RSI of 57.8 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of TMO
The score, the reasoning behind it, and what could move the price next.
TMO is in an uptrend. At $684.89, the stock trades 5.87% above its 50-day average of $646.89 and 24.60% above its 200-day average of $549.67. Near the top of its 52-week range, the price is 2.96% below the high of $705.79 and 57.35% above the low of $435.27. The 50-day average is 17.69% above the 200-day, so the averages back up the move instead of working against it.
The recent returns are all positive: the price rose 22.40% over the past three months, rose 46.33% over the past six months and rose 19.63% over the past year. Volume in the last session ran 31.5% below its average, on a day the price rose 1.64%. The 14-day RSI of 57.8 is in the neutral zone, and the MACD line is positive.
New analyst coverage ›
CLSA started coverage at Outperform on September 3, 2026.
Source: Analyst action, CLSA, September 3, 2026Rating reaffirmed ›
Morgan Stanley kept its Overweight rating on October 13, 2026.
Source: Analyst action, Morgan Stanley, October 13, 2026
Earnings beat, but the stock fell ›
The October 21, 2026 report beat the EPS estimate by 4.38%, and the share price fell 2.52% in the first session after it.
Source: Earnings report, October 21, 2026
- Keep an eye on the two nearest levels: the 52-week high at $705.79 above the price, and the 20-day EMA at $672.28 below it.
- A 14-day RSI of 57.8 falls in the neutral zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- The share price fell 2.52% in the first session after the October 21, 2026 report, even though TMO has beaten estimates in 7 of the 7 reports in our data.
The uptrend rests on TMO staying above its 50-day average at $646.89 and its 200-day average at $549.67; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $672.28.
The next level overhead is the 52-week high at $705.79.
Technical indicators
Momentum and trend for TMO, from its daily closes.
As of October 26, 2026, with TMO at $684.89, its 14-day RSI is 57.8 (neutral territory), its 50-day simple moving average is $646.89 and its 200-day is $549.67.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What TMO moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, TMO's 1-year correlation of daily returns is +0.41 with S&P 500 (SPY), +0.30 with Nasdaq 100 (QQQ), +0.16 with Bitcoin (BTC) and +0.06 with gold (XAU).
TMO price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
24 of 28 analysts rate it a buy or strong buy, 3 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $721.50 is 5.3% above the price.More buy ratings than three months ago ›
24 of 28 rate it a buy now, against 22 of 28 three months ago.
TMO Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | Maintains | Overweight |
| Oct 13, 2026 | TD Cowen | Maintains | Buy |
| Oct 7, 2026 | Barclays | Maintains | Overweight |
| Sep 9, 2026 | UBS | Assumes | Buy |
| Sep 3, 2026 | CLSA | Initiates | Outperform |
| Jul 27, 2026 | Piper Sandler | Maintains | Neutral |
As of October 26, 2026, 28 Wall Street analysts cover TMO: 24 rate it a buy or strong buy, 3 a hold and 1 a sell or strong sell. Their 12-month price targets range from $560.00 to $800.00. The median TMO price target is $721.50, 5.3% above the price of $684.89.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
TMO trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
TMO trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from TMO's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much TMO tends to move, against the market and on its own.
TMO price history and drawdowns
TMO's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.61% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 39.9%, from December 2021 to June 2025, regained by September 2026.Most 1-year holds ended higher ›
76% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $47,215, against $42,015 in the S&P 500 (SPY).
TMO Drawdowns & Recovery
As of October 26, 2026, TMO's worst peak-to-trough fall over the last 10 years with dividends reinvested was -39.9% (December 2021 to June 2025); it regained that peak by September 2026, 15 months after the low, and 76% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into TMO in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: TMO beat the S&P 500 over this period: $47,215 against $42,015.
A $10,000 investment in TMO in October 2016 would be worth about $47,215 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to TMO, and which have not.
Strongest month, July: an average of +9.98%, up in 9 of 10 years.
Weakest month, February: an average of -2.48%, up in 3 of 10 years.
This month, October: has averaged +1.89%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, TMO's strongest calendar month has been July (average +9.98%, up in 9 of 10 years) and its weakest February (average -2.48%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
TMO stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in TMO, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in TMO today could grow to about $14,415 by 2030 in the base case, with a 90th-percentile outcome near $28,544 and a 10th-percentile outcome around $7,280. The simulation models price only; at today's 0.27% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
TMO Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $987 for TMO by 2030 in the base case, from $685 today (1.4x over 4 years). The 10th-percentile path ends near $499. These are outcomes of a Monte Carlo simulation run on TMO's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $533 | $750 | $1,056 | |
| 2028 | $507 | $822 | $1,333 | |
| 2029 | $499 | $901 | $1,628 | |
| 2030 | $499 | $987 | $1,955 |
Method: a lognormal simulation of TMO's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
TMO insider trading
What the people running the company have bought and sold.
TMO insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought TMO shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, TMO insiders reported 34 open-market sales worth $172.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Gianluca Pettiti
President
|
Sell | 4.1K | $2.5M |
| Aug 31, 2026 | Gianluca Pettiti
President
|
Option | 3.7K | $1.2M |
| Aug 24, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 275 | $172.4K |
| Aug 24, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 275 | $85.1K |
| Aug 21, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 20.0K | $12.6M |
| Aug 21, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 20.0K | $6.2M |
| Aug 19, 2026 | Lisa P Britt
Officer
|
Sell | 11.4K | $7.0M |
| Aug 19, 2026 | Lisa P Britt
Officer
|
Option | 11.4K | $4.8M |
| Aug 11, 2026 | Michael D Shafer
Officer
|
Sell | 25.5K | $15.3M |
| Aug 11, 2026 | Michael D Shafer
Officer
|
Option | 25.5K | $9.4M |
| Aug 7, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 4.9K | $2.9M |
| Aug 7, 2026 | Joseph R. Holmes
Officer
|
Sell | 420 | $245.6K |
| Aug 7, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 275 | $85.1K |
| Aug 7, 2026 | Joseph R. Holmes
Officer
|
Option | 420 | $130.0K |
| Aug 6, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 15.0K | $8.6M |
| Aug 6, 2026 | Lisa P Britt
Officer
|
Sell | 5.9K | $3.4M |
| Aug 6, 2026 | Lisa P Britt
Officer
|
Option | 5.9K | $1.8M |
| Aug 6, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $3.1M |
| Aug 5, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 15.0K | $8.6M |
| Aug 5, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $3.1M |
| Jul 27, 2026 | Gianluca Pettiti
President
|
Sell | 400 | $226.0K |
| May 20, 2026 | Nelson J Chai
Director
|
Grant | 499 | - |
| May 20, 2026 | Ruby R Chandy
Director
|
Grant | 499 | - |
| May 20, 2026 | C. Martin Harris, M.D.
Director
|
Grant | 499 | - |
| May 20, 2026 | Tyler Jacks
Director
|
Grant | 499 | - |
| May 20, 2026 | Jennifer M Johnson
Director
|
Grant | 499 | - |
| May 20, 2026 | R Alexandra Keith
Director
|
Grant | 499 | - |
| May 20, 2026 | Karen S. Lynch
Director
|
Grant | 499 | - |
| May 20, 2026 | Debora L Spar
Director
|
Grant | 499 | - |
| May 20, 2026 | Scott M Sperling
Director
|
Grant | 499 | - |
| May 20, 2026 | Dion J Weisler
Director
|
Grant | 499 | - |
| Apr 27, 2026 | Gianluca Pettiti
President
|
Sell | 400 | $185.1K |
| Mar 11, 2026 | Michael D Shafer
Officer
|
Sell | 1.6K | $802.5K |
| Mar 5, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 4.0K | $2.1M |
| Mar 5, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 4.0K | $1.2M |
| Mar 4, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 10.0K | $5.1M |
| Mar 4, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $3.1M |
| Feb 25, 2026 | Lisa P Britt
Officer
|
Grant | 2.0K | - |
| Feb 25, 2026 | Marc N Casper
Chief Executive Officer
|
Grant | 14.8K | - |
| Feb 25, 2026 | Joseph R. Holmes
Officer
|
Grant | 770 | - |
| Feb 25, 2026 | Michel Lagarde
Chief Operating Officer
|
Grant | 2.2K | - |
| Feb 25, 2026 | Frederick M. Lowery
Officer
|
Grant | 1.6K | - |
| Feb 25, 2026 | Gianluca Pettiti
Officer
|
Grant | 5.8K | - |
| Feb 25, 2026 | Michael D Shafer
Officer
|
Grant | 4.7K | - |
| Feb 25, 2026 | Thomas B Shropshire Jr.
General Counsel
|
Grant | 978 | - |
| Feb 25, 2026 | Stephen Williamson
Chief Financial Officer
|
Grant | 1.5K | - |
| Feb 9, 2026 | Gianluca Pettiti
Officer
|
Sell | 400 | $216.5K |
| Dec 10, 2025 | Scott M Sperling
Director
|
Grant | 4.4K | - |
| Dec 4, 2025 | Michel Lagarde
Chief Operating Officer
|
Sell | 22.0K | $12.4M |
| Dec 4, 2025 | Michel Lagarde
Chief Operating Officer
|
Option | 40.7K | $4.9M |
| Dec 3, 2025 | Michel Lagarde
Chief Operating Officer
|
Sell | 62.0K | $36.1M |
| Dec 3, 2025 | Michel Lagarde
Chief Operating Officer
|
Option | 104.0K | $10.9M |
| Dec 2, 2025 | Frederick M. Lowery
Officer
|
Sell | 13.8K | $8.2M |
| Dec 2, 2025 | Frederick M. Lowery
Officer
|
Option | 13.8K | $3.5M |
| Nov 25, 2025 | Michael D Shafer
Officer
|
Sell | 10.7K | $6.4M |
| Nov 25, 2025 | Michael D Shafer
Officer
|
Option | 10.7K | $2.8M |
| Nov 14, 2025 | Stephen Williamson
Chief Financial Officer
|
Grant | 433 | - |
| Nov 13, 2025 | Michel Lagarde
Chief Operating Officer
|
Sell | 4.6K | $2.8M |
| Nov 13, 2025 | Michel Lagarde
Chief Operating Officer
|
Option | 4.6K | $1.2M |
| Nov 12, 2025 | Lisa P Britt
Officer
|
Sell | 1.1K | $622.1K |
| Nov 10, 2025 | Gianluca Pettiti
Officer
|
Sell | 3.0K | $1.7M |
| Nov 10, 2025 | Gianluca Pettiti
Officer
|
Option | 3.0K | $845.7K |
| Nov 7, 2025 | Lisa P Britt
Officer
|
Sell | 10.2K | $5.8M |
| Nov 7, 2025 | Lisa P Britt
Officer
|
Option | 8.5K | $2.2M |
| Oct 27, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 24.4K | $13.9M |
| Oct 27, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 24.4K | $6.2M |
| Oct 24, 2025 | Gianluca Pettiti
Officer
|
Sell | 400 | $229.7K |
| Sep 5, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 400 | $200.2K |
| Sep 5, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 400 | $101.6K |
| Aug 29, 2025 | Joseph R. Holmes
Officer
|
Sell | 385 | $189.7K |
| Aug 29, 2025 | Joseph R. Holmes
Officer
|
Option | 385 | $97.8K |
| Aug 22, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 10.0K | $5.0M |
| Aug 22, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $2.5M |
| Aug 20, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 496 | $248.0K |
| Aug 20, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 496 | $126.0K |
| Aug 7, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 18.0K | $8.2M |
| Aug 7, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 18.0K | $4.6M |
| Jul 25, 2025 | Gianluca Pettiti
Officer
|
Sell | 400 | $192.0K |
| Jun 2, 2025 | Thomas B Shropshire Jr.
General Counsel
|
Grant | 5.4K | - |
| May 21, 2025 | Nelson J Chai
Director
|
Grant | 565 | - |
| May 21, 2025 | Ruby R Chandy
Director
|
Grant | 565 | - |
| May 21, 2025 | C. Martin Harris, M.D.
Director
|
Grant | 565 | - |
| May 21, 2025 | Tyler Jacks
Director
|
Grant | 565 | - |
| May 21, 2025 | Jennifer M Johnson
Director
|
Grant | 565 | - |
| May 21, 2025 | R Alexandra Keith
Director
|
Grant | 565 | - |
| May 21, 2025 | Karen S. Lynch
Director
|
Grant | 565 | - |
| May 21, 2025 | James Charles Mullen
Director
|
Grant | 565 | - |
| May 21, 2025 | Debora L Spar
Director
|
Grant | 565 | - |
| May 21, 2025 | Scott M Sperling
Director
|
Grant | 565 | - |
| May 21, 2025 | Dion J Weisler
Director
|
Grant | 565 | - |
| May 12, 2025 | Gianluca Pettiti
Officer
|
Sell | 400 | $164.4K |
| Apr 28, 2025 | Gianluca Pettiti
Officer
|
Sell | 300 | $129.0K |
Source: TwelveData, from SEC Form 4 filings
TMO stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.